The EF-hand calcium-binding protein tescalcin is a potential oncotarget in colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Tescalcin (TESC), an EF-hand calcium-binding protein, exhibits differential tissue expression.
• The role and expression of TESC in colorectal cancer (CRC) remain largely uninvestigated.
• Understanding TESC's function in CRC is crucial for identifying new diagnostic and therapeutic strategies.

Purpose of the Study:

• To investigate the expression patterns of TESC in colorectal cancer tissues and serum.
• To elucidate the functional role of TESC in colorectal cancer cell proliferation and tumor growth.
• To evaluate TESC as a potential diagnostic biomarker and therapeutic target for CRC.

Main Methods:

• Quantitative assessment of TESC mRNA and protein levels using RT-PCR, real-time PCR, and immunohistochemistry.
• Serum TESC quantification via sandwich ELISA in colorectal cancer patients.
• Functional studies involving TESC knockdown (siRNA, shRNA) in cell proliferation assays, phospho-MAPK arrays, and mouse xenograft models.

Main Results:

• TESC was significantly overexpressed in colorectal cancer tissues but absent in normal mucosa and premalignant lesions.
• Elevated serum TESC levels were observed in patients diagnosed with colorectal cancer.
• TESC knockdown suppressed colorectal cancer cell survival by inhibiting the Akt-dependent NF-κB pathway and reduced tumor growth in vivo.

Conclusions:

• Tescalcin (TESC) is a promising diagnostic biomarker for colorectal cancer, detectable in serum.
• TESC plays a critical role in colorectal cancer progression, making it a potential therapeutic oncotarget.
• Targeting TESC may offer a novel strategy for colorectal cancer treatment.